Alexander, Veronica J.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 669

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 528

Targeting APOC3 in the familial chylomicronemia syndrome

Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 491

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 377

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 271

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 231

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 214

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III

Pechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 171

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 170

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia

Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 165

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 103

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

Alexander, V. J., Karwatowska-Prokopczuk, E., Prohaska, T. A., Li, L., Geary, R. S., Gouni-Berthold, I., Oral, E. A., Hegele, R. A., Stroes, E. S. G., Witztum, J. L., et al. (2024) · New England Journal of Medicine

Pancreatitis Pathology and TreatmentLipid metabolism and disorders

Cited by 85

Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study

Blom, D. J., O'Dea, L., Digenio, A., Alexander, V. J., Karwatowska-Prokopczuk, E., Williams, K. R., Hemphill, L., Muñiz-Grijalvo, O., Santos, R. D., Baum, S., et al. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 82

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 78

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

Marston, N. A., Bergmark, B. A., Alexander, V. J., Prohaska, T. A., Kang, Y. M., Moura, F. A., Zimerman, A., Waldman, E., Weinland, J., Murphy, S. A., et al. (2026) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 62

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance

Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 59

Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial

Gouni-Berthold, I., Alexander, V., Digenio, A., DuFour, R., Steinhagen-Thiessen, E., Martin, S., Moriarty, P., Hughes, S., Jones, R., Witztum, J. L., et al. (2017) · Atherosclerosis Supplements

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 21